Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship

被引:105
作者
Andrews, CW
Bennett, L
Yu, LX
机构
[1] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
[2] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA
关键词
bioavailability; quantitative structure-bioavailability relationship; Lipinski's Rule of Five;
D O I
10.1023/A:1007556711109
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this investigation was to develop a quantitative structure-bioavailability relationship (QSBR) model for drug discovery and development. Methods. A database of drugs with human oral bioavailability was assembled in electronic form with structure in SMILES format. Using that database, a stepwise regression procedure was used to link oral bioavailability in humans and substructural fragments in drugs. The regression model was compared with Lipinski's Rule of Five. Results. The human oral bioavailability database contains 591 compounds. A regression model employing 85 descriptors was built to predict the human oral bioavailability of a compound based on its molecular structure. Compared to Lipinski's Rule of Five, the false negative predictions were reduced from 5% to 3% while the false positive predictions decreased from 78% to 53%. A set of substructural descriptors was identified to show which fragments tend to increase/ decrease human oral bioavailability. Conclusions. A novel quantitative structure-bioavailability relationship (QSBR) was developed. Despite a large degree of experimental error, the model was reasonably predictive and stood up to crossvalidation. When compared to Lipinski's Rule of Five, the QSBR model was able to reduce false positive predictions.
引用
收藏
页码:639 / 644
页数:6
相关论文
共 10 条
[1]   Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? [J].
Ajay ;
Walters, WP ;
Murcko, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3314-3324
[2]  
BENET LZ, 1996, PHARMACOL BASIS THER, P1707
[3]  
CHAMBERS JM, 1992, STAT MODELS, P22
[4]  
Fecik RA, 1998, MED RES REV, V18, P149, DOI 10.1002/(SICI)1098-1128(199805)18:3<149::AID-MED2>3.0.CO
[5]  
2-X
[6]   Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].
Lipinski, CA ;
Lombardo, F ;
Dominy, BW ;
Feeney, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25
[7]  
*PRIC, 1999, PHARM 2005 INT REV R
[8]   A scoring scheme for discriminating between drugs and nondrugs [J].
Sadowski, J ;
Kubinyi, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3325-3329
[9]  
SIETSEMA WK, 1989, INT J CLIN PHARM TH, V27, P179
[10]   An integrated model for determining causes of poor oral drug absorption [J].
Yu, LX .
PHARMACEUTICAL RESEARCH, 1999, 16 (12) :1883-1887